I’ve tested tech for more than a decade, and it’s always been a bit difficult to find the best Android tablet for most people. Unlike the relatively simple decision of finding the best iPad — where 90 ...

TheFly reported on June 30 that Canaccord reduced its price target on DFTX to $58 from $60 while reaffirming a Buy rating on ...

Get the most out of your training and smash your next race with our guide to the best electrolyte sachets, tablets, liquids and more ...

Detailed price information for Definium Therapeutics Inc (DFTX-Q) from The Globe and Mail including charting and trades.

Definium Therapeutics DFTX shares surged 49.8% after the company announced positive top-line results from a late-stage study evaluating its lead pipeline candidate, DT120 orally disintegrating tablet ...

Definium Therapeutics Inc. DFTX shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults ...

Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of ...

A tablet, these days, can be anything you want it to be. You can dedicate it to reading, watching movies, or gaming; tap and swipe your way around for work or play; or even connect it to an external ...

What Is It, and Why Does It Matter? Cavhanza (nilotinib) is a new FDA-approved orally disintegrating tablet (ODT) formulation of nilotinib, a prescription medicine used to treat a type of blood cancer ...

CAVHANZA™ (nilotinib) Orally Disintegrating Tablets: A New, FDA-approved Treatment Offering PPI and H2RA Flexibility for Ph+ CML Patients1 Cycle Pharmaceuticals (Cycle) announces the FDA approval of ...

Poland's prime minister has said Nato is "disintegrating" after the United States announced it would withdraw thousands of troops from Germany. Donald Tusk wrote on social media: "The greatest threat ...

Andy is a seasoned technology journalist with more than 15 years experience in the mobile industry, writing for Digital Trends, Wired, and more. Andy has reviewed hundreds of smartphones and tablets, ...